Breast Cancer

For breast cancer patients aged 66 years and older, nurses should consider comorbidities when discussing prognosis, according to an analysis of Surveillance, Epidemiology and End Results–Medicare data.

CHICAGO—Exemestane appears to be a good alternative to tamoxifen for prevention of breast cancer in postmenopausal women, according to results of the randomized, placebo-controlled MAP.3 trial.

Trastuzumab is a monoclonal antibody that affects the human epidermal growth factor receptor-2 (HER2).  Trastuzumab is frequently used in young women diagnosed with HER2 breast cancer. A new study by Dr César Serrano et al published in Annals of Oncology found that trastuzumab increases the risk of heart problems, particularly in elderly women with a history of heart disease, diabetes, or both.

Breast cancer patients with no response to tamoxifen may overcome resistance to the widely-used drug when taken in combination with the leukemia chemotherapy dasatinib, new research from the Kimmel Cancer Center at Jefferson suggests.

About 70% of breast cancer diagnoses are estrogen receptor (ER)–positive disease, which indicates that the tumor may respond to tamoxifen. However, up to 35% of these ER-positive tumors have little to no response to the drug or ultimately develop resistance to it.

New breast cancer screening guidelines recommend mammography screening annually for women beginning at age 40. The American College of Obstetricians and Gynecologists (ACOG) believes that the high incidence of breast cancer combined with the potential to reduce deaths from it when caught early warrants this change from its previous recommendations (every 1-2 years starting at age 40; annually beginning at age 50).

In young women with early-stage breast cancer, coupling the GnRH analogue triptorelin with chemotherapy led to a 17% reduction in the occurrence of early menopause, according to a report in the July 20 issue of JAMA.

The phase 3 study results showed:

In young women with early-stage breast cancer, coupling the GnRH analogue triptorelin with chemotherapy led to a 17% reduction in the occurrence of early menopause, according to a report in the July 20 issue of JAMA.

The phase III study results showed:

Maintaining a healthy body weight is important for all patients. But, this is especially true for women with a breast cancer diagnosis, as an analysis of the California Teachers Study has shown a correlation between breast cancer deaths and body mass index (BMI).

Maintaining a healthy body weight is important for all patients. But, this is especially true for women with a breast cancer diagnosis, as an analysis of the California Teachers Study has shown a correlation between breast cancer deaths and body mass index (BMI).

Obesity (defined as BMI ≥30 kg/m²) increased a woman’s risk of dying of their breast cancer by 69%, compared with women with a BMI <25. For patients who were overweight at 18 years of age (defined as BMI 25-29), a similar increased risk in breast cancer mortality was detected.

Patients with HER2+ breast cancer who develop resistance to trastuzumab may soon have an alternative therapy, according to recent findings published in Clinical Cancer Research.

Page 14 of 18
Results 131 - 140 of 173